KDM7A: A Potential Drug Target for Histone Demethylation (G80853)

Target Name: KDM7A

NCBI ID: G80853

KDM7A

KDM7A: A Potential Drug Target for Histone Demethylation

Histone demethylation is a critical process that plays a significant role in various cellular processes, including cell growth, development, and gene regulation. KDM7A, a protein that belongs to the JMJC domain family, is known to be a histone demethylase that has been extensively studied for its role in various cellular processes. In this article, we will discuss the research on KDM7A and its potential as a drug target or biomarker.

KDM7A is a 21-kDa protein that is expressed in various tissues, including brain, heart, and liver. It is localized to the nuclear envelope and is involved in the demethylation of various gene promoters, including those of neurotransmitter receptors. The JMJC domain is a unique feature of KDM7A that gives it a structural identity and contributes to its function. The JMJC domain is a protein-coding domain that is characterized by the presence of a specific aromatic amino acid residue.

Several studies have demonstrated the role of KDM7A in various cellular processes, including cell growth, apoptosis, and neurotransmission. For example, researchers have shown that KDM7A plays a critical role in the regulation of cell cycle progression, and that its expression is involved in the G1/S transition. Additionally, KDM7A has been shown to be involved in the regulation of cell apoptosis, and that its expression is associated with the sensitivity of cancer cells to chemotherapy drugs.

In addition to its role in cellular processes, KDM7A has also been shown to be a potential drug target. Researchers have identified several potential drug targets for KDM7A, including the interaction with DNA, the modulation of gene expression, and the regulation of cellular processes. One of the most promising potential drug targets for KDM7A is the interaction with DNA, which is thought to play a role in the regulation of gene expression and the development of cancer.

The interaction between KDM7A and DNA has been studied extensively, and several studies have shown that the JMJC domain of KDM7A is involved in the regulation of DNA methylation. This interaction between KDM7A and DNA has important implications for the regulation of gene expression, including the regulation of cancer development.

Another potential drug target for KDM7A is the regulation of cellular processes, including cell apoptosis. Researchers have shown that KDM7A is involved in the regulation of cell apoptosis, and that its expression is associated with the sensitivity of cancer cells to chemotherapy drugs. This suggests that KDM7A may be a useful biomarker for the assessment of cancer patient outcomes, including the response to chemotherapy.

In conclusion, KDM7A is a protein that has been extensively studied for its role in various cellular processes, including cell growth, apoptosis, and neurotransmission. The JMJC domain of KDM7A is a unique feature that gives it a structural identity and contributes to its function. Several studies have demonstrated the role of KDM7A in various cellular processes, including the regulation of cell cycle progression, apoptosis, and neurotransmission. In addition, KDM7A has also been shown to be a potential drug target, with several potential drug targets, including the interaction with DNA and the regulation of cellular processes. Further research is needed to fully understand the role of KDM7A in various cellular processes and its potential as a drug target or biomarker.

Protein Name: Lysine Demethylase 7A

Functions: Histone demethylase required for brain development. Specifically demethylates dimethylated 'Lys-9', 'Lys-27' and 'Lys-36' (H3K9me2, H3K27me2, H3K36me2, respectively) of histone H3 and monomethylated histone H4 'Lys-20' residue (H4K20Me1), thereby playing a central role in histone code (PubMed:20023638, PubMed:20622853). Specifically binds trimethylated 'Lys-4' of histone H3 (H3K4me3), affecting histone demethylase specificity: in presence of H3K4me3, it has no demethylase activity toward H3K9me2, while it has high activity toward H3K27me2. Demethylates H3K9me2 in absence of H3K4me3 (PubMed:20023638). Has activity toward H4K20Me1 only when nucleosome is used as a substrate and when not histone octamer is used as substrate (PubMed:20622853)

The "KDM7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets